Table 2.
Detailed outcome and radiographic response data for STING clinical trial.
| Dog identifier | 1 | 2 | 3 | 4 | 5 |
| Dose—first injection | 5 μg | 5 μg | 15 μg | 20 μg | 15 μg |
| Dose—second injection | 5 μg | 10 μg | 20 μg | 20 μg | — |
| PFS (weeks) | 0 | 11 | 16 | 22 | 0 |
| OS (weeks) | 33 | 11 | 39 | 31 | 0 |
| Contrast-enhancing tumor volume—baseline (cm3) | 1.75 | 2.42 | 14.4 | 0.79 | 0.025 |
| Contrast-enhancing tumor volume at first recheck (cm3) | 2.64 | 1.8 | 6.34 | 0.19 | — |
| Contrast-enhancing tumor volume at second recheck (cm3) | 3.31 | — | — | 0.0 | — |
| Contrast-enhancing tumor volume at third recheck (cm3) | — | — | — | 1.1 | — |